Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05679271

Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

Intracranial Dural Arteriovenous Fistula Related Pulsatile Tinnitus . Endovascular Treatment by Venous Stenting : An Efficacy Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
University Hospital, Bordeaux · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this randomized trial to assess the angiographic efficacy of venous stenting in dural arteriovenous fistulae (DAVF) via improvment on Cognard's Classification as compared to no intervention at 6 months Participants belonging to experimental group will be treated using venous stenting. DAVF will be assessed by angiography at 6 months follow-up. Participants belonging to control group will be followed accordingly to standard of care (no treatment). After 6 months, control group patients can be treated by any means accordinlgly to standard of care.

Detailed description

DAVF are frequently revealed as a cause of invalidating pulsatile tinnitus (PT). Endovascular treatment (EVT) of DAVF using liquid embolic agent (LEA) is currently performed when an hemorrhagic risk of intracranial hemorrhage is identified (high grade DAVF). PT alone may not be a sufficient condition to offer EVT because procedure-related risks may overcome clinical benefits specifically in case of extended shunts requiring complex procedures. Stenting of dural sinus may represent an alternative to LEA-EVT with a simple and low risk procedure. Thus PT could be cured even in case of low grade DAVF without neurologic risk.

Conditions

Interventions

TypeNameDescription
DEVICEVenous stentingvenous stenting associated to antiaggregation protocol
OTHERStandard of careobservation: no treatment

Timeline

Start date
2024-08-22
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2023-01-10
Last updated
2025-02-11

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05679271. Inclusion in this directory is not an endorsement.